Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.

doi:10.1158/1078-0432.CCR-20-2718

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2021

Liu Chen, Lu Hengyu, Wang Hongyun, Loo Alice, Zhang Xiamei, Yang Guizhi, Kowal Colleen, Delach Scott, Wang Ye, Goldoni Silvia, Hastings William D, Wong Karrie, Gao Hui, Meyer Matthew J, Moody Susan E, LaMarche Matthew J, Engelman Jeffrey A, Williams Juliet A, Hammerman Peter S, Abrams Tinya J, Mohseni Morvarid, Caponigro Giordano, Hao Huai-Xiang

Abstract excerpt

PURPOSE: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently feedback activated in response to targeted therapies including RTK inhibitors and MAPK inhibitors. We seek to evaluate the efficacy and synergistic mechanisms of combinations with a novel SHP2 inhibitor, TNO155, to inform their clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Drug Synergism

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Tumor-Associated Macrophages

Source

Open in PubMed

Identifiers

PMID: 33046519
DOI: 10.1158/1078-0432.CCR-20-2718

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.PMID 33046519Read ↗

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLCSemantic proximity Read ↗

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read ↗

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.Semantic proximity Read ↗

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in NeuroblastomaSemantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF <sup>V600E</sup> colorectal tumorsSemantic proximity Read ↗

SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCERSemantic proximity Read ↗

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.Semantic proximity Read ↗

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsSemantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.